www.mdedge.com/jcso/hphemonc Hematology-Oncology Volume 12, Part 6 19
Genomic Testing in Early-Stage Breast Cancer
assays and expanding the applicability to
node-positive breast cancers. Furthermore,
with several studies now showing benefit from
the use of extended endocrine therapy, some
of these assays may be able to identify the
subset of patients who are at increased risk
for late recurrence and who might benefit
from extended endocrine therapy. Advances
in molecular testing has enabled clinicians to
offer more personalized treatments to their
patients, improve patients’ compliance, and
decrease anxiety and conflict associated with
management decisions. Although small numbers of patients with HER2-positive and triple-negative breast cancers were also included in
some of these studies, use of genomic assays
in this subset of patients is very limited and
currently not recommended.
1. Welch HG, Prorok PC, O’Malley AJ, Kramer BS.
Breast-cancer tumor size, overdiagnosis, and mam-mography screening effectiveness. N Engl J Med
2. Goss PE, Ingle JN, Pritchard KI, et al. Extending
aromatase-inhibitor adjuvant therapy to 10 years. N
Engl J Med 2016;375:209–19.
3. Mamounas E, Bandos H, Lembersky B. A randomized, double-blinded, placebo-controlled clinical
trial of extended adjuvant endocrine therapy
with letrozole in postmenopausal women with
hormone-receptor-positive breast cancer who have
completed previous adjuvant treatment with an
aromatase inhibitor. In: Proceedings from the San
Antonio Breast Cancer Symposium; December
6–10, 2016; San Antonio, TX. Abstract S1-05.
4. Tjan-Heijnen VC, Van Hellemond IE, Peer PG, et
al: First results from the multicenter phase III DATA
study comparing 3 versus 6 years of anastrozole after
2-3 years of tamoxifen in postmenopausal women
with hormone receptor-positive early breast cancer. In: Proceedings from the San Antonio Breast
Cancer Symposium; December 6–10, 2016; San
Antonio, TX. Abstract S1-03.
5. Blok EJ, Van de Velde CJH, Meershoek-Klein
Kranenbarg EM, et al: Optimal duration of
extended letrozole treatment after 5 years of adjuvant endocrine therapy. In: Proceedings from the
San Antonio Breast Cancer Symposium; December
6–10, 2016; San Antonio, TX. Abstract S1-04.
6. Effects of chemotherapy and hormonal therapy
for early breast cancer on recurrence and 15-year
survival: an overview of the randomised trials.
Early Breast Cancer Trialists’ Collaborative Group.
7. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:
8. Coates AS, Winer EP, Goldhirsch A, et al. Tailoring
therapies--improving the management of early
breast cancer: St Gallen International Expert
Consensus on the Primary Therapy of Early Breast
Cancer 2015. Ann Oncol 2015;26:1533–46.
9. Hanahan D, Weinberg RA. The hallmarks of cancer.
10. Urruticoechea A, Smith IE, Dowsett M. Proliferation
marker Ki-67 in early breast cancer. J Clin Oncol 2005;
11. de Azambuja E, Cardoso F, de Castro G Jr, et al.
Ki-67 as prognostic marker in early breast cancer: a
meta-analysis of published studies involving 12,155
patients. Br J Cancer 2007;96:1504– 13.
12. Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic
value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196
patients. Breast Cancer Res Treat 2015;153:477–91.
13. Cheang MC, Chia SK, Voduc D, et al. Ki67 index,
HER2 status, and prognosis of patients with luminal
B breast cancer. J Natl Cancer Inst 2009;101:736–50.
14. Cuzick J, Dowsett M, Pineda S, et al. Prognostic
value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth
factor receptor 2 immunohistochemical score
and com-parison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol
15. Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol 2013;66:512–6.
16. Denkert C, Budczies J, von Minckwitz G, et al.
Strategies for developing Ki67 as a useful biomarker
in breast cancer. Breast 2015; 24 Suppl 2:S67–72.
BOARD REVIEW QUESTIONS
Test your knowledge of this topic.
Go to www.mdedge.com/jcso/hphemonc for
Board Review Questions on this topic.